Hillevax
Yahoo Finance • 7 months ago
10 Buy-Rated Stocks with Latest Insider Purchases
In this article, we will take a detailed look at the 10 Buy-Rated Stocks with Latest Insider Purchases. For a quick overview of such stocks, read our article5 Buy-Rated Stocks with Latest Insider Purchases. Insider trading and its relatio... Full story
Yahoo Finance • last year
HilleVax to Present at Upcoming Investor Conferences
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the at the Guggenheim 5... Full story
Yahoo Finance • last year
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 2023 Cantor Global... Full story
Yahoo Finance • last year
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has closed its previously announced un... Full story
Yahoo Finance • last year
HilleVax Announces Pricing of Public Offering of Common Stock
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its public offering of 8,000,00... Full story
Yahoo Finance • last year
HilleVax Announces Proposed Public Offering of Common Stock
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to... Full story
Yahoo Finance • last year
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30,... Full story
Yahoo Finance • last year
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31,... Full story
Yahoo Finance • last year
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Nanette Cocero, Ph.D., MBA, t... Full story
Yahoo Finance • 2 years ago
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
BOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 3... Full story
Yahoo Finance • 2 years ago
HilleVax Announces Executive Management Appointments and Promotions
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Ozzie Berger as Senior Vice... Full story
Yahoo Finance • 2 years ago
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Mo... Full story
Yahoo Finance • 2 years ago
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results from a prespecified immunogenicity analy... Full story
Yahoo Finance • 2 years ago
HilleVax to Participate in November Investor Conferences
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Secu... Full story
Yahoo Finance • 2 years ago
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended Septembe... Full story
Yahoo Finance • 2 years ago
HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
Enrollment of remaining subjects in NEST-IN1 has resumed Immunogenicity results from the first 200 subjects expected in Q4 2022 BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical... Full story
Yahoo Finance • 2 years ago
HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate
Pan-Ig and HBGA blocking antibody responses persisted to year 5 No adverse events deemed related to HIL-214 BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on... Full story
Yahoo Finance • 2 years ago
HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
Initiated Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants (NOR-212) Completed Upsized Initial Public Offering Raising $230 Million in Gross Proceeds BOSTON, Ju... Full story
